Galderma Research & Development

Galderma Research & Development Snc

Johannes Voegel

Etienne Thoreau

Laurence Clary

Laurent Chantalat

Michel Rivier

Carine Rosignoli

Sandrine Rethore

André Jomard

Philippe Martel

Thibaud Biadatti

Claire Bouix-Peter

Philippe Andres

Andre Jomard

Emmanuelle At

Itaru Suzuki

Catherine Soulet

Jérôme Aubert

Isabelle Carlavan

Veronique Parnet

Carole Chomat

Marie-Thérèse Cavey

Véronique Parnet

A system comprising a combination of at least one MCI R receptor agonist and a source of NB-UVB, wherein said system is adapted for simultaneous or sequential use of said MC1R receptor agonist and said NB-UVB in amounts effective for the treatment and/or prevention of dermatological conditions linked to a hypopigmentation.

Combination of a MC1R receptor agonist and UVB for the treatment and/or prevention of pigmentation disorders

A combination of compounds is described for the treatment and/or prevention of skin conditions linked to hypopigmentation. Also described, is a combination product that includes at least one prostaglandin receptor agonist and at least one MC1R receptor agonist, as a medicament for use simultaneously, separately or spread out over time for the treatment and/or prevention of skin conditions linked to hypopigmentation, such as vitiligo.

Combination of a prostaglandin receptor agonist and an MC1R receptor agonist for the treatment and/or prevention of pigmentation disorders

Travoprost medicament compositions for non-daily topical application are useful for simulating or inducing the growth and/or decreasing the loss and/or increasing the density and/or reducing the heterogeneity in the diameter of human hair shafts/follicles, e.g., for the treatment of androgenic alopecia, such medicament compositions being at least twice applied over a time interval of greater than 24 hours.

Topical application of travoprost for combating hair loss

Melanocortin receptor antagonist compounds, processes for preparing them and uses thereof in human medicine and cosmetics are described. Melanocortin receptor antagonist compounds corresponding to the general formula (I): compositions containing them, and processes for their preparation and their use in pharmaceutical or cosmetic compositions are also described.

Melanocortin receptor antagonist compounds, process for preparing them and use thereof in human medicine and cosmetics

Combination comprising pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, and use thereof in the treatment of atopic dermatitis The present invention relates to a composition comprising, in a physiologically acceptable carrier, pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, in racemic or isomer form, and salts thereof, for the preparation of a medicament for use in the treatment and/or prevention of atopic dermatitis.

Dermatologic compositions comprising pyrrolidone-5-carboxylic acid and at least one entity chosen from citrulline, arginine and asparagine, and uses thereof in the treatment of atopic dermatitis

Novel compounds having the general formula (I) below: are useful in a wide variety of applications in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively are formulated into cosmetic compositions.

Methods of modulating PPAR gamma-type receptors

Compounds that modulate PPAR&#x3b3;-type receptors and cosmetic/pharmaceutical compositions comprising said compounds

Compounds that modulate PPAR&#x3b3; type receptors and cosmetic/pharmaceutical compositions comprised thereof

Novel biaromatic vitamin D analogues have the general formula (I): and are suited for a wide variety of pharmaceutical applications, whether in human or veterinary medicine, and also for cosmetic applications.

Vitamin D analogues

A variety of retinoid compounds well suited for preventively or curatively treating a bacterial colonization infesting/infecting an individual subject exhibit pronounced antibacterial activity, notably pronounced antibacterial activity in respect of the bacterium, and are also well suited for the cleansing/deodorizing of human skin.

Retinoid compounds suited for antibacterial applications

Growing community of inventors

Chateauneuf/Grasse, France

Johannes Voegel